Vertex-CRISPR drug posts phase 3 wins, secures PDUFA date – FierceBiotech

by

  1. Vertex-CRISPR drug posts phase 3 wins, secures PDUFA date FierceBiotech
  2. CRSP Stock Pops As FDA Sets December Data To Potentially OK Gene-Editing Drug | Investor’s Business Daily Investor’s Business Daily
  3. FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia Yahoo Finance
  4. Gene Editing Race Between Editas and Vertex, CRISPR Heats Up BioSpace
  5. Editas posts early sickle cell data as it races to catch Vertex FierceBiotech
  6. View Full Coverage on Google News

Read original article here

Leave a Comment